

GP35-A  
Vol. 30 No. 24  
Replaces GP35-P  
Vol. 29 No. 7

---

# Development and Use of Quality Indicators for Process Improvement and Monitoring of Laboratory Quality; Approved Guideline

This document provides guidance on development of quality indicators and their use in the medical laboratory.

---

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.



# Clinical and Laboratory Standards Institute

*Advancing Quality in Health Care Testing*

Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the health care community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related health care issues. Our process is based on the principle that consensus is an effective and cost-effective way to improve patient testing and health care services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, we provide an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

## PUBLICATIONS

A document is published as a standard, guideline, or committee report.

**Standard** A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

**Guideline** A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

**Report** A document that has not been subjected to consensus review and is released by the Board of Directors.

## CONSENSUS PROCESS

The CLSI voluntary consensus process is a protocol establishing formal criteria for

- The authorization of a project
- The development and open review of documents
- The revision of documents in response to comments by users
- The acceptance of a document as a consensus standard or guideline

Most documents are subject to two levels of consensus—"proposed" and "approved." Depending on the need for field evaluation or data collection, documents may also be made available for review at an intermediate consensus level.

**Proposed** A consensus document undergoes the first stage of review by the health care community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

**Approved** An approved standard or guideline has achieved consensus within the health care community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (ie, that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

Our standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following CLSI's established consensus procedures. Provisions in CLSI standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

## COMMENTS

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are addressed by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any document. Address comments to Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

## VOLUNTEER PARTICIPATION

Health care professionals in all specialties are urged to volunteer for participation in CLSI projects. Please contact us at [customerservice@clsi.org](mailto:customerservice@clsi.org) or +610.688.0100 for additional information on committee participation.

GP35-A

ISBN 1-56238-738-3

Volume 30 Number 24

ISSN 0273-3099

---

## Development and Use of Quality Indicators for Process Improvement and Monitoring of Laboratory Quality; Approved Guideline

Michael A. Noble, MD, FRCP(C)  
Maureen E. Ahler, MSQA, MT(ASCP)  
Bette Bennett, RT  
Julie Coffey, CQA, CMQ/OE(ASQ), ART, MLT  
Kathryn Connolly, MT(ASCP); CQA (ASQ)  
Judy A. Daly, PhD  
Christine Fleming, BA, MLT  
Sonia C. Giribaldi, MT(ASCP)  
Lee Hilborne, MD, MPH, FASCP  
Elizabeth Kenimer Leibach, EdD, MS, CLS, MT  
John J. Mahoney  
Barbara Parsons, MA, MT(ASCP)  
Charles D. Reynolds, MS  
Paul Valenstein, MD

### Abstract

Clinical and Laboratory Standards Institute document GP35-A—*Development and Use of Quality Indicators for Process Improvement and Monitoring of Laboratory Quality; Approved Guideline* provides guidance on development of quality indicators and their use in the medical laboratory. These indicators include measures developed in a single laboratory for local use and indicators developed by other organizations and national bodies. The document includes criteria for development of quantitative, ordinal, and qualitative indicators; it also includes procedures for gathering data, presenting and interpreting results, monitoring performance over time, and comparing performance with other laboratories or national norms.

Clinical and Laboratory Standards Institute (CLSI). *Development and Use of Quality Indicators for Process Improvement and Monitoring of Laboratory Quality; Approved Guideline*. CLSI document GP35-A (ISBN 1-56238-738-3). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2010.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org)



Copyright ©2010 Clinical and Laboratory Standards Institute. Except as stated below, neither this publication nor any portion thereof may be adapted, copied, or otherwise reproduced, by any means (electronic, mechanical, photocopying, recording, or otherwise) without prior written permission from Clinical and Laboratory Standards Institute ("CLSI").

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, contact the Executive Vice President, Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

### **Suggested Citation**

CLSI. *Development and Use of Quality Indicators for Process Improvement and Monitoring of Laboratory Quality; Approved Guideline*. CLSI document GP35-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.

### **Proposed Guideline**

February 2009

### **Approved Guideline**

December 2010

ISBN 1-56238-738-3

ISSN 0273-3099

## Committee Membership

### Area Committee on Quality Systems and Laboratory Practices

**Carl D. Mottram, BA, RRT, RPFT, FAARC**  
**Chairholder**  
 Mayo Clinic  
 Rochester, Minnesota, USA

**Devery Howerton, PhD**  
**Vice-Chairholder**  
 Centers for Disease Control and Prevention  
 Atlanta, Georgia, USA

Eric Arendash, MT(ASCP)  
 Centers for Medicare & Medicaid Services  
 Philadelphia, Pennsylvania, USA

Lucia M. Berte, MA, MT(ASCP)SBB,  
 DLM; CQA(ASQ) CQM/OE  
 Laboratories Made Better!  
 Broomfield, Colorado, USA

Theresa Billups, MBA, MT(ASCP)DLM  
 Remel, Inc.  
 Lake Charles, Louisiana, USA

Michael B. Cohen, MD  
 University of Iowa  
 Iowa City, Iowa, USA

Nancy Dubrowny, MS, MT(ASCP)SC  
 BD Preanalytical Systems  
 Franklin Lakes, New Jersey, USA

Michelle Jenkins, MS, MT(AMT) ASQ,  
 CQE  
 Abbott Diagnostics  
 Irving, Texas, USA

Jennifer Schiffgens, MBA, MT(ASCP),  
 CLS  
 California Pacific Medical Center  
 San Francisco, California, USA

Bruce D. Tually, BAppSc, MAppSc  
 Hunter Area Pathology Service  
 New South Wales, Australia

Tonya Wilbon, BS, M(ASCP)  
 FDA Center for Devices/Radiological  
 Health  
 Rockville, Maryland, USA

#### Advisors

Susan Blonshine, RRT, RPFT, FAARC  
 TechEd Consultants, Inc.  
 Mason, Michigan, USA

Dennis J. Ernst, MT(ASCP)  
 Center for Phlebotomy Education  
 Corydon, Indiana, USA

Mark D. Kolins, MD  
 William Beaumont Hospital  
 Royal Oak, Michigan, USA

Michael A. Noble, MD, FRCP(C)  
 University of British Columbia  
 Vancouver, Canada

Albert Rabinovitch, MD, PhD  
 NovoMetrics, Inc.  
 Mountain View, California, USA

Stephen J. Sarewitz, MD  
 Eastside Pathology Inc., PS  
 Bellevue, Washington, USA

Carol A. Walker  
 Siemens Healthcare Diagnostics  
 Walpole, Massachusetts, USA

Thomas L. Williams, MD  
 Nebraska Methodist Hospital  
 Omaha, Nebraska, USA

Sheila M. Woodcock, MBA,  
 FCSMLS(D)  
 QSE Consulting  
 Rose Bay, Nova Scotia, Canada

### Subcommittee on Development and Use of Quality Indicators

**Michael A. Noble, MD, FRCP(C)**  
**Chairholder**  
 University of British Columbia  
 Vancouver, Canada

Kathryn Connolly, CQA (ASQ),  
 MT(ASCP)  
 COLA  
 Columbia, Maryland, USA

Judy A. Daly, PhD  
 University of Utah-Primary  
 Children's Medical Center  
 Salt Lake City, Utah, USA

Christine Fleming, BA, MLT  
 Quality Management Program-  
 Laboratory Services  
 Toronto, Canada

Lee Hilborne, MD, MPH  
 RAND Corporation  
 Santa Monica, California, USA

John J. Mahoney  
 LifeScan, Inc.  
 Milpitas, California, USA

Barbara Parsons, MA, MT(ASCP)  
 Johns Hopkins Medical Institutions  
 Baltimore, Maryland, USA

Charles D. Reynolds, MS  
 Centers for Medicare & Medicaid  
 Services  
 Boston, Massachusetts, USA

Paul Valenstein, MD  
 Pathology and Laboratory  
 Management Associates  
 Ann Arbor, Michigan, USA

#### Staff

Clinical and Laboratory Standards  
 Institute  
 Wayne, Pennsylvania, USA

Lois M. Schmidt, DA  
*Vice President, Standards  
 Development*

Jennifer K. Adams, MT(ASCP),  
 MSHA  
*Staff Liaison*

Melissa A. Lewis, ELS  
*Editorial Manager*

Megan P. Larrisey, MA  
*Assistant Editor*

### **Acknowledgment**

CLSI gratefully acknowledges the following individuals and organizations for their help in preparing this approved-level guideline.

Maureen E. Ahler, MSQA, MT(ASCP), Kaiser Permanente Medical Care

Bette Bennett, RT, LifeLabs Medical Laboratory Services

Julie Coffey, CQA, CMQ/OE(ASQ), ART, MLT, Quality Management Program – Laboratory Services

Sonia C. Giribaldi, MT(ASCP), Alfred I. DuPont Hospital for Children

Elizabeth Kenimer Leibach, EdD, MS, CLS, MT, Medical College of Georgia

**Contents**

Abstract.....i

Committee Membership..... iii

Foreword..... vii

1 Scope.....1

2 Introduction.....1

3 Terminology.....4

    3.1 A Note on Terminology .....4

    3.2 Definitions .....4

    3.3 Abbreviations and Acronyms .....5

4 Planning (Selection of Quality Indicators in a Laboratory).....5

    4.1 Developing a Measurement Philosophy .....5

    4.2 Identifying Concepts for Measurement (Types and Categories of Indicators).....6

    4.3 Selecting Specific Indicators.....7

5 Development of Quality Indicators in a Laboratory .....11

    5.1 Operational Definitions for Indicators .....12

    5.2 Documented Process for Data Collection .....12

    5.3 Target Setting.....14

6 Implementation of Quality Indicators in a Laboratory .....15

    6.1 Pilot Trial, Revisions .....15

    6.2 Collect Indicator Data.....15

7 Analysis, Presentation, and Interpretation of Quality Indicator Data .....15

    7.1 Data Analysis Methods .....15

    7.2 Presentation of Indicator Data .....20

8 Acting on Quality Indicator Data.....22

    8.1 Reporting Indicators to Customers, Accreditation Organizations, and Public Organizations .....23

9 Special Considerations.....23

    9.1 One-time Assessment and Monitoring Over Time .....23

    9.2 Development of Quality Indicators for Multiple Laboratories .....24

    9.3 Use of Interlaboratory Comparisons as a Quality Indicator .....25

    9.4 Accreditation Requirements.....25

10 Conclusion .....26

References.....27

Additional References.....28

Appendix A. Plan-Do-Check-Act.....29

Appendix B. Example of a Template for Developing Quality Indicators.....30

**Contents (Continued)**

Appendix C. Sample Quality Indicator: Assessing Community Provider/Physician Satisfaction  
With Laboratory Services .....31

Appendix D. Sample Quality Indicator: Rate of Mislabeled or Unlabeled Samples .....33

Appendix E. Sample Quality Indicator: Quantity Not Sufficient Rates for Sweat Testing .....34

Appendix F. Sample Quality Indicator: Verification of Abstracted Results Into the Electronic  
Medical Record .....35

Appendix G. Sample Quality Indicator: Monitoring the Timeliness of Critical Value Reporting and  
Documentation of the Read-Back of Critical Results .....36

Appendix H. Sample Quality Indicator: Blood Wastage Reduction.....37

Appendix I. Sample Data Presentation for Key Performance Indicators.....38

Summary of Delegate Comments and Subcommittee Responses.....39

The Quality Management System Approach .....52

Related CLSI Reference Materials .....53

## Foreword

With increasing awareness, the impact of medical errors can be seen on patient safety. Medical errors can result in annoyance and inconvenience such as time lost or necessitated patient revisits, but can also result in the more serious consequences of diagnostic delay or error, increased cost, inappropriate therapy, and worse, increased risk of patient illness, debility, and sometimes death. Medical errors occur throughout the health care process, in the clinical setting and also in the laboratory. An active program of quality management allows the laboratory to monitor for error with the intended goals of early detection and rapid remediation and correction, and more importantly, prevention of errors before they occur.

The process of monitoring for and addressing error does not just happen. Quality takes time to define. It requires planning of the processes and procedures that develop appropriate, measurable, interpretable information upon which action can take place in the cycle of continuous improvement. Those procedures can be referred to as quality indicators. Quality indicators are an integral component of all quality management systems, including ISO 9001,<sup>1</sup> ISO 15189,<sup>2</sup> and ISO 17025,<sup>3</sup> and the system described within CLSI document HS01.<sup>4</sup> Ideally the development of quality indicators should be based on both a risk assessment of potential errors and the frequency of observed errors.

Importantly, not all quality indicators are derived within the laboratory or are even laboratory centric. Many are recommended or required over a broader regional, state, or national network of laboratories or health care systems, based on voluntary participation, best practice recommendation, organizational mandate, or regulatory requirement. This document provides guidance in selecting and applying indicators that are developed in a single laboratory for local use and indicators developed by other organizations and national bodies.

Many organizations can benefit from guidance on selecting and developing the quality indicators they use. Experience demonstrates that poorly designed indicators can result in confusing and misleading information that leads less towards continual improvement, and more towards increased work, and often poor decision making. Others, while well designed and intended, are impractical because some laboratories do not have the resources to gather the actual information required, or do not have the capability or resources for following through with an appropriate action plan. Finally, some laboratories continue to collect information on parameters that are highly stable, rather than shift their focus, time, and energy to other indicators that may provide information that leads to change. Failure to recognize the value of information gathered is both ineffective and inefficient. The goal of this document is to highlight an effective approach to selection, development, interpretation, and application of information derived from well-designed quality indicators.

## Key Words

Continual improvement, corrective actions, evidence-based decision making, management review, measurement, metrics, preventive action, quality control, quality indicator, quality management system, remedial actions



## **Development and Use of Quality Indicators for Process Improvement and Monitoring of Laboratory Quality; Approved Guideline**

### **1 Scope**

This document provides guidance on development of quality indicators and their use in the medical laboratory. These indicators include measures developed in a single laboratory for local use and indicators developed by other organizations and national bodies. The document includes criteria for development of quantitative, ordinal, and qualitative indicators; it also includes procedures for gathering data, presenting and interpreting results, monitoring performance over time, and comparing performance with other laboratories or national norms.

This guideline is intended for use by laboratory directors, managers, supervisors, and the quality manager as a means to ensure that their laboratories implement an effective approach to selection, development, interpretation, and application of information derived from well-designed quality indicators.

### **2 Introduction**

The term “quality indicator” refers to a systematic measurement process intended to provide information about the quality of a system.<sup>5</sup> The concept of measurement as an essential part of quality dates back to the very beginnings of quality management as expressed by Walter Shewhart as “checking” within the “plan-do-check-act” (PDCA) cycle. The PDCA cycle in all its component parts provides a virtual never-ending process and is key for achieving the culture for quality transformation. An overview of the PDCA process is provided in Appendix A.

Commonly, performance of quality control (QC) equipment checks, such as measuring refrigerator or incubator temperatures, is considered as or is interpreted as a type of quality indicator. While it is accurate that QC measurements are a form of narrowly assessed metric, they are not considered quality indicators of a process, procedure, or outcome. The focus of this document more broadly addresses process measures, such as monitoring sample receipt to report turnaround time and sample collection errors. A variety of examples of process metrics is provided throughout the document.

Quality indicators can be designed to measure any aspect of laboratory service. It is helpful for management to take a broad view of laboratory operations, giving consideration to known risks and their potential consequences, before selecting a set of indicators to measure an aspect of the quality of operations. Many regulatory and accreditation requirements,<sup>1-3,6</sup> as well as laboratory guidelines and recommendations,<sup>4,7,8</sup> provide useful frameworks for identifying aspects of laboratory service that are candidates for quality indicators.

Ideally, every aspect of laboratory services is objectively and regularly monitored (eg, all 12 quality system essentials [QSEs] and all phases of the path of workflow). Unfortunately, universal monitoring is impractical. Decisions need to be made about which processes to monitor and how frequently measurements should be made. Typically, clinical laboratories are managed using a set of indicators that provide information about only a fraction of laboratory functions at specific points in time.

Some quality indicators are required by law, regulation, accrediting organizations, or contractual arrangements (eg, requirements for internal QC monitoring of analytical systems and external proficiency testing [PT]). When not required by external agencies, quality indicators are chosen by leadership based on organizational goals, risk management, strategic planning, review of data and complaints, client recommendations, and subjective assessment.